medigraphic.com
ISSN 2305-7939 (Electronic)

2021, Number 3

<< Back Next >>

RCU 2021; 10 (3)

Intravesical botulinum toxin in refractory overactive bladder and its impact on quality of life

Artés AM, Marín MFM, Bobadilla RER, García PVJ, Jiménez PJD, Guzmán Martínez-Valls PL

Language: Spanish
References: 16
Page:
PDF size: 481.20 Kb.


ABSTRACT

Background: Overactive bladder is a clinical entity with a high prevalence that causes a great impact on the quality of life. Botulinum toxin has been shown to be effective in the treatment of this pathology, improving the symptoms and life of patients.
Objective: The objective of this study is to evaluate the outcome, complications and impact of quality of life in patients with refractory overactive bladder after intravesical application of botulinum toxin.
Material and methods: It is carried out a prospective study of 85 patients with overactive bladder refractory to medical treatment and in whom intravesical injection of 100 UI of botulinum toxin was performed between 2016 and 2018. The characteristics of the patients, complications and the results of the questionnaires OAB-V8 (Overactive Bladder), ICIQ-SF (Urinary incontinence) and the SF-36 Health Questionnaire (Quality of life) before and after the application of the treatment have been reviewed. For the comparison of results, the Student’s t-test for paired data or Wilcoxon was used. A value of p < 0.05 was considered statistically significant.
Results: The most frequent complication was to present a high postvoid residual in 16.47% of the patients, followed by a positive urine culture in 9.41%. The changes in the parameters of the questionnaires after the month of application, compared to the pre-application assessment, were statistically significant for OAB-V8 scale and for ICIQ-SF questionnaire, but not for the Health Questionnaire SF-36. The most affected dimensions were the physical and social function and the physical and emotional role.
Conclusions: The intravesical application of botulinum toxin is a safe and well tolerated procedure, with minimal complications, which reduces episodes of urgency and urinary incontinence, improving the quality of life of patients.


REFERENCES

  1. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;(12):CD005493. PMID: 22161392. DOI: http://dx.doi.org/10.1002/14651858.CD005493.pub3

  2. Pérez RJ, Reyes MA. Vejiga hiperactiva y su manejo con toxina botulínica tipo A en el Hospital General de México. Rev Mex Urol. 2010 [acceso 13/10/2020];70(4):228–42. Disponible en: https://www.medigraphic.com/pdfs/uro/ur-2010/ur104h.pdf

  3. Siddiqui N, Reynolds WS. Botulinum toxin for treatment of lower urinary tract conditions: Indications and clinical evaluation. UpToDate. 2020 [acceso 28/10/2020]. Disponible en: https://www.uptodate.com/contents/botulinum-toxin-for-treatment-of-lower-urinary-tract-conditions-indications-and-clinical-evaluation

  4. Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, et al. EAU Guidelines on Urinary Incontinence in Adults. 2019 [acceso 13/10/2020]. Disponible en: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urinary-Incontinence-2019.pdf

  5. Hsieh P, Chiu H, Chen K, Chang C, Chou EC. Overactive Bladder. Toxins (Basel). 2016;8(59):1–12. DOI: http://dx.doi.org/10.3390/toxins8030059

  6. Brenes F, Angulo J, Ochayta D, Rejas J, Arumí D, Cañadas A, Lizarraga I. Validación psicométrica de las escalas OAB-V8 y OAB-V3 para la detección de pacientes con probable vejiga hiperactiva en la población española. Medicina Clínica. 2014;143(12):521-9. DOI: http://dx.doi.org/10.1016/j.medcli.2013.10.032

  7. Busquets M, Serra R. Validación del cuestionario International Consultation on Incontinence Questionnaire Short-Form (ICIQ-SF) en una población chilena usuaria del Fondo Nacional de Salud (FONASA). Rev Med Chile. 2012;140:340-6. DOI: http://dx.doi.org/10.4067/S0034-98872012000300009

  8. Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, Santed R, Valderas JM, Ribera A, Domingo-Salvany A, Alonso J. El Cuestionario de Salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit. 2005 [acceso 13/10/2020];19(2):135-50. Disponible en: https://scielo.isciii.es/pdf/gs/v19n2/revision1.pdf

  9. Srikrishna S, Robinson D, Cardozo L, Vella M. Management of overactive bladder syndrome. Postgr Med J. 2007;83:481–6. DOI: http://dx.doi.org/10.1136/pgmj.2007.057232

  10. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology. 2004 Jun;63(6):1071-5. DOI: http:///dx.doi.org/10.1016/j.urology.2004.01.041. PMID: 15183952

  11. Álvarez RL, González R, Elizalde VM. Calidad de vida como respuesta al tratamiento intravesical con toxina botulínica tipo A, en el síndrome de vejiga hiperactiva refractaria a tratamiento convencional. Rev Chil Obs Ginecol. 2016;81(1):9–14. DOI: http://dx.doi.org/10.4067/S0717-75262016000100002

  12. Durán-Ortiz S, García-Herrera DA, Pérez-Hernández BO, Pérez Zavala, R.; León S. Aplicación intravesical de toxina botulínica y su repercusión en la calidad de vida de pacientes con lesión medular y vejiga neurogénica. Experiencia institucional. Rev Mex Urol. 2017;77(6):453-463. DOI: http://dx.doi.org/10.24245/revmexurol.v77i6.1179

  13. Trial P, Chapple C, Sievert K, Macdiarmid S, Khullar V, Radziszewski P, et al. On a botulinum toxin A 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinenc: A Randomised. Eur Urol. 2013;64(2):249–56. DOI: http://dx.doi.org/10.1016/j.eururo.2013.04.001

  14. Mahajan T. Botulinum toxin for treatment of overactive bladder: Injection and complications. UpToDate. 2020 [acceso 28/10/2020]. Disponible en: https://www.uptodate.com/contents/botulinum-toxin-for-treatment-of-overactive-bladder-injection-and-complications

  15. Gong Q, Xu Y, Xu J, Ding X, Guo C, Hanson C. Meta-analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients with Overactive Bladder. Front Pharmacol. 2020;10(January):1–16. PMID: 32009968; PMCID: PMC6974921. DOI: http://dx.doi.org/10.3389/fphar.2019.01618

  16. Doherty A, Hennessey DB, Onggo JR, Ranasinghe W, Gani J. Modifications to Botulinum toxin A delivery in the management of detrusor overactivity recalcitrant to initial injections: a review. World J Urol. 2019 May;37(5):891-8. DOI: http://dx.doi.org/10.1007/s00345-018-2456-7




2020     |     www.medigraphic.com